<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551563</url>
  </required_header>
  <id_info>
    <org_study_id>SUSI_1</org_study_id>
    <nct_id>NCT01551563</nct_id>
  </id_info>
  <brief_title>Stavanger University Hospital Inflammatory Bowel Disease Trial</brief_title>
  <acronym>SUSI</acronym>
  <official_title>Management of Inflammatory Bowel Disease in the Stavanger Area - a Prospective Evaluation of Standardized Treatment Regimens on Disease Outcome With Focus on Mucosal Healing and Associations to Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at studying the outcomes of a protocol-based handling of newly diagnosed
      Inflammatory bowel disease ( IBD ) patients within a defined uptake area in Norway. It is a
      descriptive study and no hypothesis is predefined.

      Cytokine studies, QoL and fatigue assessment will be included for hypothesis-generating
      purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      none considered needed
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy of IBD drug therapy</measure>
    <time_frame>5 years</time_frame>
    <description>Endoscopic, clinical and biochemical response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue in patients with coeliac disease - substudy</measure>
    <time_frame>1 year</time_frame>
    <description>Fatigue at diagnosis and after one year of gluten free diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue in IBD</measure>
    <time_frame>5 years</time_frame>
    <description>Fatigue at diagnosis and during follow-up</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>IBD</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and mucosal biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All newly diagnosed IBD patients (Crohns and Ulcerative colitis) within Stavanger Univ
        Hospital catchment area
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed IBD

        Exclusion Criteria:

          -  previous IBD with specific treatment within 10 year

          -  inability to consent

          -  inability to adhere to treatment protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tore Grimstad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>tore grimstad</last_name>
    <email>tore.bjorn.grimstad@sus.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lars aabakken</last_name>
    <email>larsaa@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SUS</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tore B Grimstad, MD PhD</last_name>
      <phone>+47909 21 650</phone>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

